This document summarizes the top 20 global pharma brands in 2012 according to IMS Health MIDAS data. It lists each brand's global rank, market size, growth percentage, generic name, and major indication. The top brand was fluticasone propionate/salmeterol xinafoate for asthma, with $8.9 billion in sales and 1.7% growth. Adalimumab for rheumatoid arthritis was second with $8.5 billion in sales and 18.5% growth. Rosuvastatin for lipid lowering was third with $8.3 billion in sales and 3.0% growth. The document was presented by Masum Chowdhury, Manager of Strategic Brand

1. Top 20 Global Pharma Brand
in 2012
(IMS Health MIDAS 2012)
Presented By
Masum Chowdhury
Manager, SBMD
Asiatic Laboratories Ltd.

2. Global Rank 1 Brand 2012
Market Size: 8.9 Billion US$
Growth: 1.7%
Generic:
Fluticasone propionate/
Salmeterol xinafoate
Major Indication:
Asthma

3. Global Rank 2 Brand 2012
Market Size: 8.5 Billion US$
Growth: 18.5%
Generic:
Adalimumab
Major Indication:
Rheumatoid Arthritis

4. Global Rank 3 Brand 2012
Market Size: 8.3 Billion US$
Growth: 3.0%
Generic:
Rosuvastatin
Major Indication:
Lipid Lowering Agent

5. Global Rank 4 Brand 2012
Market Size: 7.5 Billion US$
Growth: (7.2%)
Generic:
Esomeprazole
Major Indication:
Peptic Ulcer

6. Global Rank 5 Brand 2012
Market Size: 7.5 Billion US$
Growth: 9.7%
Generic:
Etanercept
Major Indication:
Rheumatoid Arthritis,
Ankylosing Spondylitis

7. Global Rank 6 Brand 2012
Market Size: 7.3 Billion US$
Growth: 10.6%
Generic:
Inflikimab
Major Indication:
Rheumatoid Arthritis,
Ankylosing Spondylitis
Ulcerative Colitis

8. Global Rank 7 Brand 2012
Market Size: 7.0 Billion US$
Growth: 11.5%
Generic:
Aripiprazole
Major Indication:
Depression
Bipolar disorder
Schizophrenia.

9. Global Rank 8 Brand 2012
Market Size: 6.6 Billion US$
Growth: 19.3%
Generic:
Insulin glargine 100 iu/ml
Major Indication:
Type 1 diabetes mellitus (Children)
Type 2 diabetes mellitus (Adults)

10. Global Rank 9 Brand 2012
Market Size: 6.0 Billion US$
Growth: 8.8%
Generic:
Rituximab
Major Indication:
non-Hodgkin’s lymphoma

11. Global Rank 10 Brand 2012
Market Size: 5.8 Billion US$
Growth: 23.2%
Generic:
Duloxetine
Major Indication:
Major Depressive Disorder

12. Global Rank 11 Brand 2012
Market Size: 5.4 Billion US$
Growth: 4.5%
Generic:
Bevacizumab
Major Indication:
Metastatic colorectal cancer (colon cancer),
Non–small cell lung cancer
Glioblastoma

13. Global Rank 12 Brand 2012
Market Size: 5.2 Billion US$
Growth: (44.9%)
Generic:
Clopidogrel
Major Indication:
Recent MI,
Recent Stroke

14. Global Rank 13 Brand 2012
Market Size: 5.1 Billion US$
Growth: 9.9%
Generic:
Tiotropium Bromide
Major Indication:
Bronchospasm in people with
bronchitis, emphysema, or COPD

15. Global Rank 14 Brand 2012
Market Size: 5.1 Billion US$
Growth: (60.7)
Generic:
Atorvastatin
Major Indication:
Lipid lowering Agent

16. Global Rank 15 Brand 2012
Market Size: 5.0 Billion US$
Growth: 9.0%
Generic:
Trastuzumab
Major Indication:
Breast Cancer

17. Global Rank 16 Brand 2012
Market Size: 4.7 Billion US$
Growth: (25.2%)
Generic:
Montelukast
Major Indication:
Asthmatic Inflammation

18. Global Rank 17 Brand 2012
Market Size: 4.6 Billion US$
Growth: 13.9%
Generic:
Pregabalin
Major Indication:
Diabetic Neuropathy
Neuropathic Pain

19. Global Rank 18 Brand 2012
Market Size: 4.5 Billion US$
Growth: 11.4%
Generic:
Glatiramer Acetate
Major Indication:
Relapsing-Remitting Multiple
Sclerosis

20. Global Rank 19 Brand 2012
Market Size: 4.3 Billion US$
Growth: 3.8%
Generic:
Imatinib
Major Indication:
Acute Lymphoblastic Leukemia
Hypereosinophilic
Syndrome/Eosinophilic Leukemia

21. Global Rank 20 Brand 2012
Market Size: 4.3 Billion US$
Growth: 2.1%
Generic:
Pegfilgrastym
Major Indication:
Febrile neutropenia

22. Thanks

23. Prepared By
Masum Chowdhury
Manager,
Strategic Brand Management Department
Asiatic Laboratories Ltd.
masum.pha@gmail.com,
+880-0171-7642874, +880-0193 7990014